You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameAzapropazone
Accession NumberDB07402
TypeSmall Molecule
GroupsWithdrawn
DescriptionNot Available
Structure
Thumb
Synonyms
Azapropazone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RheumoxAmdipharm Mercury Company Limited
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIK2VOT966ZI
CAS number13539-59-8
WeightAverage: 298.3397
Monoisotopic: 298.14297584
Chemical FormulaC16H18N4O2
InChI KeyWOIIIUDZSOLAIW-NSHDSACASA-N
InChI
InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
IUPAC Name
(4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione
SMILES
[H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 5-androstenedione.Experimental, Illicit
AbciximabAzapropazone may increase the anticoagulant activities of Abciximab.Approved
AcebutololAzapropazone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone.Approved
AcenocoumarolAzapropazone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azapropazone.Approved, Vet Approved
AclarubicinAzapropazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azapropazone.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.Approved
AliskirenAzapropazone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololAzapropazone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Azapropazone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Amcinonide.Approved
AmikacinAzapropazone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAzapropazone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinAzapropazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodAzapropazone may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Azapropazone is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Anisodamine.Investigational
annamycinAzapropazone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.Approved
Antithrombin III humanAzapropazone may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Azapropazone may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanAzapropazone may increase the anticoagulant activities of Apixaban.Approved
ApramycinAzapropazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Azapropazone.Approved, Investigational
ArbekacinAzapropazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinAzapropazone may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanAzapropazone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAzapropazone may decrease the antihypertensive activities of Arotinolol.Approved
AtenololAzapropazone may decrease the antihypertensive activities of Atenolol.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone.Approved
BalsalazideAzapropazone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminAzapropazone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAzapropazone may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azapropazone.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azapropazone.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azapropazone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Betamethasone.Approved, Vet Approved
BetaxololAzapropazone may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Betulinic Acid.Investigational
BevantololAzapropazone may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azapropazone.Approved, Investigational
BisoprololAzapropazone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAzapropazone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAzapropazone may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azapropazone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bucillamine.Investigational
BucindololAzapropazone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Budesonide.Approved
BufuralolAzapropazone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideAzapropazone may decrease the diuretic activities of Bumetanide.Approved
BupranololAzapropazone may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azapropazone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azapropazone.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azapropazone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Azapropazone.Approved, Vet Approved, Withdrawn
CarteololAzapropazone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAzapropazone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Celecoxib.Approved, Investigational
CeliprololAzapropazone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAzapropazone may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.Approved
CinoxacinAzapropazone may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinAzapropazone may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidAzapropazone may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azapropazone.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Azapropazone is combined with Curcumin.Investigational
CyclosporineAzapropazone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Azapropazone is combined with D-Limonene.Investigational
Dabigatran etexilateAzapropazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAzapropazone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAzapropazone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinAzapropazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Azapropazone is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinAzapropazone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azapropazone.Approved
DextranAzapropazone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Azapropazone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Azapropazone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Azapropazone may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azapropazone.Approved, Vet Approved
DicoumarolAzapropazone may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Azapropazone.Approved
DihydrostreptomycinAzapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Azapropazone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azapropazone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azapropazone.Approved
DoxorubicinAzapropazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneAzapropazone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Azapropazone is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ebselen.Investigational
Edetic AcidAzapropazone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAzapropazone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azapropazone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azapropazone.Approved
EnoxacinAzapropazone may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinAzapropazone may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole.Approved
EpirubicinAzapropazone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAzapropazone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.Approved
EquileninThe risk or severity of adverse effects can be increased when Azapropazone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Equilin.Approved
EsmololAzapropazone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone sulfate.Approved
Etacrynic acidAzapropazone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.Approved, Investigational
Ethyl biscoumacetateAzapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Azapropazone is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Azapropazone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azapropazone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Azapropazone.Vet Approved
FleroxacinAzapropazone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Azapropazone.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fludrocortisone.Approved
FluindioneAzapropazone may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAzapropazone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Azapropazone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azapropazone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azapropazone.Approved, Nutraceutical, Vet Approved
FondaparinuxAzapropazone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAzapropazone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.Approved
FramycetinAzapropazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAzapropazone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateAzapropazone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAzapropazone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAzapropazone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Azapropazone.Approved, Withdrawn
GemifloxacinAzapropazone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAzapropazone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAzapropazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAzapropazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinAzapropazone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Azapropazone is combined with HE3286.Investigational
HeparinAzapropazone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Higenamine.Investigational
HirulogAzapropazone may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Azapropazone.Investigational
HydralazineAzapropazone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone.Approved
Hygromycin BAzapropazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone.Approved
IdarubicinAzapropazone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxAzapropazone may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Azapropazone.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.Approved
IndenololAzapropazone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Indoprofen.Withdrawn
INNO-206Azapropazone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Azapropazone is combined with Istaroxime.Investigational
KanamycinAzapropazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone.Approved
LabetalolAzapropazone may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Azapropazone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Azapropazone.Approved, Investigational
LepirudinAzapropazone may increase the anticoagulant activities of Lepirudin.Approved
LevobunololAzapropazone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAzapropazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Azapropazone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azapropazone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Azapropazone.Approved
LomefloxacinAzapropazone may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Azapropazone.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azapropazone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Azapropazone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone.Approved
ME-609The risk or severity of adverse effects can be increased when Azapropazone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azapropazone.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.Approved, Vet Approved
MesalazineAzapropazone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Azapropazone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAzapropazone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.Approved
MetoprololAzapropazone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideAzapropazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azapropazone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azapropazone.Approved
MoxifloxacinAzapropazone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nabumetone.Approved
NadololAzapropazone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAzapropazone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAzapropazone may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azapropazone.Approved
Nalidixic AcidAzapropazone may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Azapropazone is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Azapropazone.Investigational
NeamineAzapropazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinAzapropazone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAzapropazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.Approved
NetilmicinAzapropazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nitroaspirin.Investigational
NorfloxacinAzapropazone may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinAzapropazone may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.Approved
OlsalazineAzapropazone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Azapropazone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Orgotein.Vet Approved
OtamixabanAzapropazone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Azapropazone.Approved
OxprenololAzapropazone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Parecoxib.Approved
ParomomycinAzapropazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinAzapropazone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAzapropazone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAzapropazone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateAzapropazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azapropazone.Approved
PhenindioneAzapropazone may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonAzapropazone may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azapropazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.Approved, Investigational
PindololAzapropazone may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinAzapropazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAzapropazone may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.Approved, Investigational
PlicamycinAzapropazone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azapropazone.Approved
PractololAzapropazone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Azapropazone.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Azapropazone can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Propacetamol.Approved
PropranololAzapropazone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Azapropazone.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Azapropazone.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Azapropazone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Azapropazone.Vet Approved
Protein CAzapropazone may increase the anticoagulant activities of Protein C.Approved
Protein S humanAzapropazone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAzapropazone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAzapropazone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone.Investigational
PuromycinAzapropazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azapropazone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.Experimental, Investigational
ReviparinAzapropazone may increase the anticoagulant activities of Reviparin.Approved
RibostamycinAzapropazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.Approved, Investigational
RivaroxabanAzapropazone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinAzapropazone may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Azapropazone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azapropazone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Azapropazone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Azapropazone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone.Approved, Investigational
SisomicinAzapropazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolAzapropazone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAzapropazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAzapropazone may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinAzapropazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Azapropazone.Approved
SpironolactoneAzapropazone may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Azapropazone.Investigational
StreptomycinAzapropazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAzapropazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineAzapropazone may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone.Approved
SulodexideAzapropazone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Azapropazone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.Approved, Withdrawn
TacrolimusAzapropazone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Azapropazone.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Azapropazone.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azapropazone.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.Approved, Investigational
TemafloxacinAzapropazone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Azapropazone.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azapropazone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azapropazone.Approved
TiludronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tiludronate.Approved, Vet Approved
TimololAzapropazone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tixocortol.Approved
TobramycinAzapropazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.Approved
TorasemideAzapropazone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azapropazone.Approved
TranilastThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAzapropazone may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Azapropazone.Approved
TrovafloxacinAzapropazone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Azapropazone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinAzapropazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Azapropazone.Approved
WarfarinAzapropazone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAzapropazone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Azapropazone may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Azapropazone.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.Withdrawn
ZorubicinAzapropazone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24,
1967; assigned to Siegfried AG, Switzerland
Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2,
1969; assigned to Siegfried AG.

General ReferencesNot Available
External Links
ATC CodesM01AX04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9389
Caco-2 permeable+0.5728
P-glycoprotein substrateNon-substrate0.5961
P-glycoprotein inhibitor IInhibitor0.8281
P-glycoprotein inhibitor IIInhibitor0.6484
Renal organic cation transporterNon-inhibitor0.7843
CYP450 2C9 substrateNon-substrate0.8218
CYP450 2D6 substrateNon-substrate0.8107
CYP450 3A4 substrateSubstrate0.6289
CYP450 1A2 substrateInhibitor0.5528
CYP450 2C9 inhibitorNon-inhibitor0.8735
CYP450 2D6 inhibitorNon-inhibitor0.9188
CYP450 2C19 inhibitorNon-inhibitor0.8614
CYP450 3A4 inhibitorNon-inhibitor0.8273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.725
Ames testAMES toxic0.5466
CarcinogenicityNon-carcinogens0.8321
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4784 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7311
hERG inhibition (predictor II)Non-inhibitor0.8171
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point187Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
Predicted Properties
PropertyValueSource
Water Solubility0.641 mg/mLALOGPS
logP0.92ALOGPS
logP2.08ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)0.52ChemAxon
pKa (Strongest Basic)7.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.22 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity85.69 m3·mol-1ChemAxon
Polarizability31.94 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTriazines
Sub ClassAminotriazines
Direct ParentAminotriazines
Alternative Parents
Substituents
  • Aminotriazine
  • Amino-1,2,4-triazine
  • 1,2,4-triazine
  • Benzenoid
  • 1,3-dicarbonyl compound
  • Pyrazolidinone
  • Pyrazolidine
  • Tertiary amine
  • Guanidine
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:21 / Updated on August 17, 2016 12:24